STENTYS

About the deal

PARIS – April 30, 2018 – 6.00 pm CEST – STENTYS (FR0010949404 — STNT), a medical technology company commercializing the Xposition S self-apposing coronary stent, today announces the completion of the acquisition of MINVASYS, independent specialist in innovative coronary devices marketed worldwide, and the issuance of 596,805 new shares in partial payment of the acquisition.

Christophe Lottin, Chief Executive Officer of STENTYS, says: “The completion of the acquisition of MINVASYS, the first external growth operation of the STENTYS group, is a decisive step in our intention to create a benchmark French player in interventional cardiology. I wish to thank all the stakeholders involved in this structuring project for the future of STENTYS, and in particular our shareholders who have contributed, thanks to their participation in our recent capital increase, to the realization of this acquisition. Today, our group can focus its efforts on the launch of a joint commercial offer, represented by a range of innovative proprietary products, via a commercial and distribution network covering over 60 countries. Through the pooling of our know-how, our complementary technologies and the significant organizational and production synergies, we will have solid short-, medium- and long-term growth levers.